Journal of Controlled Release 2024

14 papers
The 2024 volume of the Journal of Controlled Release highlights advancements in stimuli-responsive drug delivery systems and multi-functional biomaterials. Research themes focus heavily on oncology, with studies investigating pH and glutathione-responsive nano-herb delivery for colorectal cancer and reactive oxygen species-responsive hydrogels for chemoimmunotherapy. Other significant work explores metabolic targeting, such as using nanodiamonds to impair tumor glycolysis, and synergistic treatments for non-small cell lung cancer through dual-inhibitor co-assemblies. Beyond oncology, the journal features research on regenerative medicine and inflammatory conditions. Notable examples include hydrogel-bioactive glass dressings designed to enhance neurogenesis in infected wounds and Janus nanocomposites for periodontitis therapy. Prolific contributors for the year include authors such as Biao Dong, Chunyan Li, and Jong Seung Kim. These publications emphasize the development of coordinative modular assemblies and spatiotemporal delivery mechanisms to improve therapeutic precision. The 2024 edition reflects a trend toward integrating nanotechnology with immunotherapy to address complex pathological environments.

Papers

Title
A coordinative modular assembly-constructed self-reinforced nano-therapeutic agent for effective antitumor-immune activation
A pH and glutathione-responsive carbon monoxide-driven nano-herb delivery system for enhanced immunotherapy in colorectal cancer
Apigenin-7-glucoside-loaded nanoparticle alleviates intestinal ischemia-reperfusion by ATF3/SLC7A11-mediated ferroptosis
Brain targeted biomimetic siRNA nanoparticles for drug resistance glioblastoma treatment
Corrigendum to “Gold core@CeO2 halfshell Janus nanocomposites catalyze targeted sulfate radical for periodontitis therapy” [Journal of Controlled Release 370 (2024) 600–613]
Corrigendum to “Golgi-customized Trojan horse nanodiamonds impair GLUT1 plasma membrane localization and inhibit tumor glycolysis [371 (2024) 338–350]”
Exploring the optimal chain length of modification module in disulfide bond bridged paclitaxel prodrug nanoassemblies for breast tumor treatment
Gold core@CeO2 halfshell Janus nanocomposites catalyze targeted sulfate radical for periodontitis therapy
“Golgi-customized Trojan horse” nanodiamonds impair GLUT1 plasma membrane localization and inhibit tumor glycolysis
Healing with precision: A multi-functional hydrogel-bioactive glass dressing boosts infected wound recovery and enhances neurogenesis in the wound bed
In situ formed reactive oxygen species-responsive dipyridamole prodrug hydrogel: Spatiotemporal drug delivery for chemoimmunotherapy
Peptide targeting improves the delivery and therapeutic index of glucocorticoids to treat rheumatoid arthritis
Subconjunctival injection of microcrystalline prodrug of dexamethasone for long-acting anti-inflammation after phacoemulsification surgery
Therapeutic co-assemblies for synergistic NSCLC treatment through dual topoisomerase I and tubulin inhibitors